ClinicalTrials.gg
Not yet recruitingNCT07505134Updated Oct 7, 2026

Exploring the Influence of Glucagon-like Peptide -1 (GLP-1) Medications on Food Cravings, Food Selection, and Food Intake Following Exposure to Food Advertisements

An interventional study of Food advertisements and Tech advertisements in GLP - 1, sponsored by Penn State University. Not yet recruiting. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Penn State University · Not applicable, Interventional, and Other

How we know

Updated Oct 7, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Study summary

The purpose of this randomized control trial is to compare how food cravings, food selection, and food consumption change in response to frequent food advertisements compared to non-food advertisements in adults taking GLP-1 (weight loss) medications. The primary question we aim to answer is: do GLP-1 medications reduce an individual's vulnerability to external triggers that drive food cravings and consumption?

Participants will:

  • report daily food consumption for a total of 10 days,
  • receive eight daily prompts to view food or non-food related advertisements, and respond to a short 9-question survey for 7 days,
  • answer several questionnaires,
  • and complete two in-person visits to complete a virtual reality food selection task.
02

Conditions studied

  • GLP - 1

Keywords

  • GLP-1
  • Food choice
  • Cravings
  • Food cue reactivity
03

In context

Lead sponsor

Penn State University is the lead sponsor of 271 studies on the registry; 54 are open to participants now.

Of its 15 completed or terminated interventional studies of FDA-regulated products, 11 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults (18+) with overweight or obesity ( >25 kg/m2)
  • On an injectable form of tirzepatide GLP-1 medication at a minimum dose of 7.5 mg, taking it as prescribed by their doctor
  • Not currently taking an incretin-based medication at baseline other than the GLP-1 medication
  • Fluent in English

Exclusion criteria

Exclusion Criteria:

  • Do not have consistent access to a smart phone that can access the study software
  • Diagnosed with cognitive or physical disability or epilepsy
  • Adults taking a compound GLP-1
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Food advertisement group

    Advertisements viewed daily by this group will be food and/or beverage products

    Behavioral: Food advertisements

  • Placebo comparator
    Tech advertisement group

    Individuals in this group will only receive tech-related advertisements daily

    Behavioral: Tech advertisements

Interventions

  • BehavioralFood advertisements

    Videos and images of food and beverage advertisements from popular brands and/or restaurants

  • BehavioralTech advertisements

    Video and photo advertisements of popular tech tools

06

What researchers measure

Primary outcomes

  1. Mean food cue reactivity scores in the afternoon

    Average scores of craving levels for each group following afternoon advertisement viewing sessions

    Time frame: 7-day period of all afternoon survey responses

  2. Mean food cue reactivity scores in the morning

    Average scores of craving levels for each group following morning advertisement viewing sessions

    Time frame: 7-day period of all morning survey responses

  3. Mean food cue reactivity scores in the evening

    Average scores of craving levels for each group following evening advertisement viewing sessions

    Time frame: 7-day period of all evening survey responses

  4. Mean food cue reactivity scores overall

    Average scores of craving levels for each group over all viewing sessions

    Time frame: 7-day period of all survey responses

  5. Energy density of consumed foods

    The energy density profile of foods consumed each day

    Time frame: 7 days

Secondary outcomes

  1. Change from baseline in energy density of foods selected in the virtual buffet

    Time frame: Baseline and 7 days

  2. Changes in food noise since being on medication questionnaire

    Questionnaire assessing various aspects of food noise at present compared to before the medication

    Time frame: Baseline

  3. Changes in reasons for purchasing foods questionnaire

    A questionnaire that assesses how five factors impact purchasing choices, and how the main factors have changed between prior to starting the medication and after.

    Time frame: Baseline

  4. Individual Food Cue Responsiveness--Trait

    Time frame: Baseline

  5. Change in brand familiarity, liking, and/or craving

    A questionnaire that measures the familiarity, liking, and craving of each brand the participant will be exposed to (baseline) or has been exposed to (after intervention).

    Time frame: Baseline and 7 days

07

Study locations

No study locations are listed for this record.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Sep 2026; primary completion for Dec 2026, 3 months later.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 7, 2026: start May 2026 → Sep 2026, primary completion Aug 2026 → Dec 2026 and completion Sep 2026 → Dec 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2026
First posted
Apr 1, 2026
StartEst.
Sep 2026was May 2026
Primary completionEst.
Dec 2026was Aug 2026
CompletionEst.
Dec 2026was Sep 2026
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
May 2026→Sep 2026
Oct 7, 2026
Primary completion
Aug 2026→Dec 2026
Oct 7, 2026
Study completion
Sep 2026→Dec 2026
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    Start date May 2026→Sep 2026
    Primary completion Aug 2026→Dec 2026
    Study completion Sep 2026→Dec 2026
    + 1 other change: responsible party

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07505134
Collaborators
Penn State Health
Responsible party
Travis Masterson (Assistant Professor and Director of the Health, Ingestive Behavior, and Technology Lab, Penn State University) — Principal investigator
First posted
Apr 1, 2026
Start date
Sep 2026 (estimated)
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Oct 7, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion